Stay updated on Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Sign up to get notified when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.

Latest updates to the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page
- Check5 days agoChange DetectedAdded Revision: v3.3.3 to the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedMinor system revision updating from v3.3.1 to v3.3.2, with no visible changes to study content, eligibility, or contact details.SummaryDifference0.2%

- Check34 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; the page now displays the new revision label and removes the previous one.SummaryDifference0.1%

- Check41 days agoChange DetectedThe banner about the lapse in government funding and NIH operating status was removed.SummaryDifference0.4%

- Check48 days agoChange DetectedCore study details, eligibility criteria, and endpoints appear unchanged; only minor visual/layout adjustments were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedThe update shows minor UI/formatting adjustments and section reorganization without changes to the study's key details.SummaryDifference0.4%

Stay in the know with updates to Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.